Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

74.09EUR
8:23am EDT
Change (% chg)

€-0.76 (-1.02%)
Prev Close
€74.85
Open
€73.96
Day's High
€75.05
Day's Low
€73.00
Volume
1,216
Avg. Vol
1,812
52-wk High
€81.75
52-wk Low
€59.00

Latest Key Developments (Source: Significant Developments)

Lilly Q1 non-GAAP earnings per share $0.98
Tuesday, 25 Apr 2017 06:25am EDT 

April 25 (Reuters) - Eli Lilly And Co ::Lilly reports first-quarter 2017 results.Q1 revenue $5.228 billion versus I/B/E/S view $5.21 billion.Sees FY 2017 earnings per share $2.60 to $2.70.Q1 non-GAAP earnings per share $0.98.Q1 loss per share $0.10.Sees FY 2017 revenue $21.8 billion to $22.3 billion.Q1 earnings per share view $0.96 -- Thomson Reuters I/B/E/S.Eli Lilly And Co - qtrly Cymbalta sales $174.6 million versus $198.7 million.For Q1 of 2017, Alimta generated worldwide revenue of $489.9 million, which decreased 13 percent.Fy2017 earnings per share view $4.11, revenue view $22.11 billion -- Thomson Reuters I/B/E/S.Worldwide Jardiance revenue during q1 of 2017 was $74.0 million, an increase of 94 percent.Eli Lilly And Co - "Lilly's new product launches, including trulicity and taltz, led company to a strong quarter of volume-driven revenue growth".Eli Lilly And Co - in Q1 of 2017, company recognized an acquired in-process research and development charge of $857.6 million.On a non-GAAP basis, company has reaffirmed 2017 EPS to be in range of $4.05 to $4.15.Eli Lilly - recognized acquired in-process research and development charge of $857.6 million in quarter associated with acquisition of colucid pharmaceuticals.Eli Lilly and Co - in q1 of 2016, company recognized asset impairment, restructuring and other special charges of $131.4 million.Says in Q1 2017, recognized asset impairment, restructuring and other special charges of $213.9 million.  Full Article

Novartis CEO says takeover prices have risen, focusing on early-stage targets
Tuesday, 25 Apr 2017 01:57am EDT 

April 25 (Reuters) - Novartis Ag :CEO Joe Jimenez says thinks with Cosentyx "we can hold our own" against lilly drug taltz.Says price of potential acquisitions has increased, prompting company to "go upstream" for early stage drug acquisitions.Jimenez says Entresto on track for the objectives for the year, expects growth quarter-by-quarter.Jimenez says timing of Novartis's involvement in Turkey campaign was unfortunate, but principle of supporting patients around the world remains, declined to comment on plans for campaign.  Full Article

Lilly says phase 3 MONARCH 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis
Monday, 24 Apr 2017 06:45am EDT 

April 24 (Reuters) - Eli Lilly And Co ::Lilly announces phase 3 monarch 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis.Eli Lilly and Co- trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival.Eli Lilly and Co - following monarch 3 interim analysis, Lilly intends to begin global submissions of these results in q3 of 2017.Eli Lilly and Co- intends to initiate monarch 1 and monarch 2 submissions beginning in q2 of 2017.Says adverse events were generally consistent with previous studies of abemaciclib.Eli Lilly and Co - detailed efficacy and safety results for monarch 3 will be presented at a medical meeting in second half of year.Eli Lilly and Co - improvement was shown in a key secondary endpoint of objective response rate (orr) in trial.  Full Article

U.S. FDA issues CRL for baricitinib
Friday, 14 Apr 2017 09:00am EDT 

Incyte Corp : U.S. FDA issues complete response letter for baricitinib . Letter indicates that FDA is unable to approve application in its current form . Specifically, FDA indicated that additional clinical data are needed to determine most appropriate doses . FDA also stated that additional data are necessary to further characterize safety concerns across treatment arms . "Companies disagree with agency's conclusions" . Incyte is evaluating impact of complete response on its previously-issued milestone and research and development expense guidance for 2017 .Lilly is reaffirming both its financial guidance for 2017 and its mid-term guidance for remainder of this decade.  Full Article

Eli Lilly says Lilly Endowment Inc reports open market sale of 210,000 of stock
Friday, 31 Mar 2017 12:16pm EDT 

Eli Lilly And Co :Lilly Endowment Inc reports open market sale of 210,000 of co's common stock on march 30 at $84.674 per share - SEC filing.  Full Article

Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent
Tuesday, 28 Mar 2017 08:10am EDT 

Intelgenx Technologies Corp : Intelgenx Technologies- Eli Lilly granted Intelgenx' Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent . Intelgenx Technologies Corp - any exclusivity associated with tadalafil compound patent expiring is not affected by this agreement - SEC filing . Intelgenx Technologies- exclusive license allows co to commercialize tadalafil ed versafilm product in U.S. prior to expiration of '166 dosing patent Source: (http://bit.ly/2nvYskj) Further company coverage: [IGX.V] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Eli Lilly announces $850 mln investment in U.S. capital projects in 2017
Friday, 24 Mar 2017 08:00am EDT 

Eli Lilly And Co : Lilly announces $850 million investment in U.S. capital projects in 2017 . During 2012-2016, had increased U.S manufacturing workforce by more than 1,000 employees-from 5,000 to 6,000 roles-with about 400 added in Indianapolis . Company's investments span facilities across its U.S. Enterprise . Expansion is part of five-year investment by company to expand its diabetes products manufacturing operations in U.S. . Plans for a new $85 million expansion of its Trulicity (Dulaglutide) device assembly operations in U.S. . "On a path to launch 20 new products in a 10-year time frame" . Significant investment in manufacturing diabetes medicines continues with new $85 million commitment in indianapolis . Eli Lilly and Co says more favorable tax climate could lead to additional U.S. investments .Expansion also includes a $140 million insulin cartridge production facility.  Full Article

Ignyta to explore strategic options for Taladegib through amendment of Taladegib license agreement with Lilly
Thursday, 23 Mar 2017 04:00pm EDT 

Ignyta Inc : Ignyta announces exploration of strategic options for Taladegib, enabled by amendment of Taladegib license agreement with Lilly . Ignyta - agreement amends and restates prior license, development and commercialization agreement, dated November 6, 2015, by and between Ignyta, Lilly .Ignyta Inc - entered into amended , restated license, development, commercialization agreement with Eli Lilly and company for Taladegib Oncology program.  Full Article

Lilly says phase 3 breast cancer study meets primary endpoint
Monday, 20 Mar 2017 06:45am EDT 

Eli Lilly And Co : Lilly announces phase 3 monarch 2 breast cancer study of abemaciclib met primary endpoint of progression-free survival . Eli Lilly And Co - its monarch 2 trial of abemaciclib met primary endpoint of progression-free survival (pfs) . Eli Lilly And Co- intends to submit a new drug application (nda) for single-agent abemaciclib in q2 of 2017 .Plans to submit an additional application for monarch 2 in q3 of this year.  Full Article

Eli Lilly says senior VP of corporate affairs and communications to leave
Thursday, 2 Mar 2017 06:45am EST 

Eli Lilly And Co : Lilly announces changes in senior management . Eli Lilly and Co - Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh . Eli Lilly And Co - Bart Peterson, senior vice president of corporate affairs and communications, will leave Lilly March 31 .Eli Lilly And Co - search currently is under way for Peterson's replacement.  Full Article

More From Around the Web

Photo

EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis.